Skip to main content

New Public Consultations to be Held on Classification and Harmonisation Proposals for Three Substances



New Public Consultations to be Held on Classification and Harmonisation Proposals for Three Substances

EU Regulatory Bulletin contents


Concerned parties are being invited by the European Chemicals Agency (ECHA) to submit comments on new proposals for the harmonised classification and labelling (CLH) of three substances: diisohexyl phthalate (or DIHP), tebuconazole and imazalil.

With regard to tebuconazole and imazalil the CLH proposals entail a revision of the substances' present classification status under Regulation 1272/2008 (CLP Regulation). It is proposed that tebuconazole and imazalil be classified as hazardous to the aquatic environment while their acute toxicity would be revised. In addition, it is proposed by Germany that imazalil be classified as a category 2 carcinogen.

For DIHP, which is not currently classified under the CLP Regulation, the success of the CLH proposed by Sweden would mean its inclusion in the list of substances for which harmonised classification and labelling has been established (part 3 of Annex VI to the CLP Regulation).

Each of the consultations is to last 45 days. The deadline for comments on the CLH proposal for DIHP will be21 September 2012, while for tebuconazole and imazalil the commenting period will lapse on 5 October. The comments received are to be considered by and included in the opinion of ECHA's Committee for Risk Assessment (RAC). The RAC's opinion is in turn to be taken into account by the Commission when it decides on whether or not to accept the proposals.

ECHA's website is encouraging concerned parties to identify themselves and register through a comments webform during the consultations. The Agency observes that it may, on a case-by-case basis, request registered parties to provide additional information and/or take part in 'additional targeted consultations' after the public consultation.

For more information, please contact us.

Sign up to our email digest

Click to subscribe or manage your email preferences.